Amgen's director of value, access and policy, Ian Noble, says a vision and agreed principles are essential to ensuring the pending HTA review avoids becoming just another negotiation and actually delivers for Australian patients. …
Amgen's Ian Noble - 'If it doesn't get measured, it doesn't get done'
December 14, 2021 Latest NewsBioPharmaBioPharmaDispatch ExecutivePodcast
Latest Video
New Stories
-
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - - Latest News -
UK companies are granted more time to decide on pricing agreement
September 29, 2025 - - Latest News -
Anatara strengthens board with the appointment of Dirk van Dissel
September 29, 2025 - - Australian Biotech -
CLINUVEL advances next-generation peptide drug formulations
September 29, 2025 - -
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 - - Australian Biotech -
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - - Latest News -
Chimeric reports encouraging early data from CHM CDH17 trial
September 29, 2025 - - Australian Biotech